Helen Ma1, Ahmed Sawas2. 1. Columbia University Medical Center, New York, NY, 10032, USA. 2. Columbia University Medical Center, New York, NY, 10032, USA. as4386@cumc.columbia.edu.
Abstract
PURPOSE OF REVIEW: This review is about the antibody-drug conjugate (ADC), a form of drug delivery consisting of a monoclonal antibody, linker, and cytotoxic payload. We summarize the history of ADC development, highlighting the three FDA-approved ADCs currently available. RECENT FINDINGS: Gemtuzumab ozogamicin is a CD33-targeted ADC linked to calicheamicin. It is approved for CD33+ AML in the first line or the relapsed or refractory (R/R) setting. Brentuximab vedotin is a CD30-targeted ADC bound to MMAE. It is approved for the treatment of certain R/R CD30+ lymphomas. Recently, it has been approved for first line therapy with chemotherapy in advanced HL. Inotuzumab ozogamicin is a CD22-directed ADC attached to calicheamicin indicated for the treatment of adults with R/R B cell precursor ALL. Three ADCs have been approved for the treatment of various hematologic malignancies. We discuss the pertinent human trials that led to FDA approval. We include our perspectives about drug resistance, toxicities, and future development.
PURPOSE OF REVIEW: This review is about the antibody-drug conjugate (ADC), a form of drug delivery consisting of a monoclonal antibody, linker, and cytotoxic payload. We summarize the history of ADC development, highlighting the three FDA-approved ADCs currently available. RECENT FINDINGS:Gemtuzumab ozogamicin is a CD33-targeted ADC linked to calicheamicin. It is approved for CD33+ AML in the first line or the relapsed or refractory (R/R) setting. Brentuximab vedotin is a CD30-targeted ADC bound to MMAE. It is approved for the treatment of certain R/R CD30+ lymphomas. Recently, it has been approved for first line therapy with chemotherapy in advanced HL. Inotuzumabozogamicin is a CD22-directed ADC attached to calicheamicin indicated for the treatment of adults with R/R B cell precursor ALL. Three ADCs have been approved for the treatment of various hematologic malignancies. We discuss the pertinent human trials that led to FDA approval. We include our perspectives about drug resistance, toxicities, and future development.
Authors: Robert Chen; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Joseph M Connors; Andreas Engert; Emily K Larsen; Dirk Huebner; Abraham Fong; Anas Younes Journal: Blood Date: 2016-07-18 Impact factor: 22.113
Authors: Jean-Philippe Stephan; Pamela Chan; Chien Lee; Christopher Nelson; James Michael Elliott; Charity Bechtel; Helga Raab; David Xie; Jon Akutagawa; Jakub Baudys; Ola Saad; Saileta Prabhu; Wai Lee T Wong; Richard Vandlen; Fred Jacobson; Allen Ebens Journal: Bioconjug Chem Date: 2008-07-19 Impact factor: 4.774
Authors: Paul G Richardson; Brandon M Triplett; Vincent T Ho; Nelson Chao; Fiona L Dignan; Michelle Maglio; Mohamad Mohty Journal: Expert Rev Clin Pharmacol Date: 2018-01-05 Impact factor: 5.045
Authors: June M McKoy; Cara Angelotta; Charles L Bennett; Martin S Tallman; Martha Wadleigh; Andrew M Evens; Timothy M Kuzel; Steve M Trifilio; Dennis W Raisch; Jonathan Kell; Daniel J DeAngelo; Francis J Giles Journal: Leuk Res Date: 2006-09-07 Impact factor: 3.156
Authors: A Y Liu; R R Robinson; K E Hellström; E D Murray; C P Chang; I Hellström Journal: Proc Natl Acad Sci U S A Date: 1987-05 Impact factor: 11.205
Authors: R A Larson; M Boogaerts; E Estey; C Karanes; E A Stadtmauer; E L Sievers; P Mineur; J M Bennett; M S Berger; C B Eten; M Munteanu; M R Loken; J J M Van Dongen; I D Bernstein; F R Appelbaum Journal: Leukemia Date: 2002-09 Impact factor: 11.528
Authors: James I Geller; Joseph G Pressey; Malcolm A Smith; Rachel A Kudgus; Mariana Cajaiba; Joel M Reid; David Hall; Donald A Barkauskas; Stephen D Voss; Steve Y Cho; Stacey L Berg; Jeffrey S Dome; Elizabeth Fox; Brenda J Weigel Journal: Cancer Date: 2020-09-11 Impact factor: 6.860